GlassScriptPhysician profile
Neena Varghese
NPI 1730792482
$6,007.23
in general payments reported to CMS, 2019-2025
32 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,754 · 2022: $2,376 · 2023: $1,032 · 2024: $479 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $750.63 | 2021-2024 | Optimizer, Optimizer |
| Biotronik INC. | $646.10 | 2021-2023 | Amvia Edge |
| Novartis Pharmaceuticals Corporation | $547.74 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $342.82 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.97 | 2021-2024 | Lifevest |
| Heartflow, INC. | $301.83 | 2022 | |
| Merck Sharp & Dohme LLC | $277.96 | 2021-2023 | Verquvo |
| Corcept Therapeutics | $263.43 | 2023-2025 | Korlym |
| Lilly USA, LLC | $248.62 | 2023-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $240.80 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $230.56 | 2021-2023 | Brilinta, Farxiga |
| Novo Nordisk INC | $221.76 | 2022-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $217.35 | 2022-2025 | Varithena Administration Pack, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.68 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $155.28 | 2022-2024 | Camzyos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $140.26 | 2021-2022 | |
| Altathera Pharmaceuticals LLC | $139.19 | 2023 | Sotalol Hydrochloride |
| Pfizer INC. | $134.52 | 2021-2022 | |
| Madrigal Pharmaceuticals | $127.94 | 2025 | Rezdiffra |
| Actelion Pharmaceuticals US, INC. | $104.85 | 2023 | Uptravi, Opsumit |
| Medtronic, INC. | $75.95 | 2022-2023 | Venaseal |
| Irhythm Technologies, INC. | $64.91 | 2021-2022 | |
| Insulet Corporation | $46.49 | 2025 | Omnipod |
| Dexcom, INC. | $42.93 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $37.15 | 2022 | |
| Kestra Medical Technology Services, INC. | $26.51 | 2022 | |
| Daiichi Sankyo INC. | $25.01 | 2022 | |
| Tandem Diabetes Care, INC. | $23.38 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $22.48 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.30 | 2023 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $16.18 | 2021 | |
| Cequr Corporation | $12.65 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neena Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.